香港股市 已收市

騰盛博藥-B (2137.HK)

HKSE - HKSE 延遲價格。貨幣為 HKD。
加入追蹤清單
9.160+0.590 (+6.88%)
收市價: 04:08PM HKT

騰盛博藥-B

Building 7
3rd Floor, Zhongguancun Dongsheng Intl. S No. 1 North Yongtaizhuang Road Haidian Dist.
Beijing 100192
China

https://www.briibio.com

版塊Healthcare
行業Biotechnology
全職員工113

高階主管

名稱標題支付行使價出生年份
Dr. Zhi Hong Ph.D.Co-founder, Exec. Chairman & CEO1964
Dr. Ankang Li C.F.A., J.D., Ph.D.Chief Financial & Strategy Officer and Company Sec.
Ms. Karen Del Barrio NeuendorffChief People Officer & Head of HR
Mr. Yongqing LuoPres & GM of Greater China, CEO of TSB Therapeutics and Exec. Director
Mr. Coy StoutSr. VP, Head of U.S. Market Access & Patient Advocacy
Dr. Li Yan M.D., Ph.D.Chief Medical Officer
Dr. Lianhong Xu Ph.D.Sr. VP & Head of Medicinal Chemistry
Dr. Qing Zhu Ph.D.Sr. VP & Head of Biopharmaceutical Research
Dr. David Margolis M.D., M.P.H.VP & Head of Infectious Diseases Therapy Area
截止 為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

公司管治

截至 無 止,騰盛博藥-B 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。